Press Releases Abliva AB Deutsche Boerse AG

Equities

NTP

SE0002575340

Delayed Deutsche Boerse AG Other stock markets 01:16:25 17/07/2024 pm IST			5-day change	1st Jan Change
0.0128 ^EUR	+0.79%		+70.67%	+4.07%

30/05	Abliva Concludes Dosing in Mid-stage Study of Mitochondrial Disease Drug	MT
30/05	Abliva AB Announces Completion of 24 Weeks of Dosing in Wave 1 of the Falcon Study of KL1333 in Primary Mitochondrial Disease	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Amended number of shares and votes in Abliva AB (publ)	31/05	AQ
Abliva Announces Completion of 24 Weeks of Dosing in Wave 1 of the FALCON Study of KL1333 in Primary Mitochondrial Disease	30/05	AQ
Ablivas CEO to BioStock: "We remain on track for the interim analysis early in Q3"	29/05	AQ
Resolutions from Annual General Meeting in Abliva AB (publ) on May 23, 2024	23/05	AQ
Abliva : Interim Report January - March 2024	23/05	PU
Abliva AB Interim Report January – March 2024	23/05	AQ
Abliva to Host Virtual KOL Event on KL1333 in Primary Mitochondrial Disease on May 21, 2024	13/05	AQ
Amended number of shares and votes in Abliva AB (publ)	30/04	AQ
Abliva resolves on a directed issue of shares to guarantors in connection with the completed rights issue	25/04	AQ
Abliva AB Publishes 2023 Annual Report	24/04	AQ
Notice of Annual General Meeting of Abliva AB (publ)	22/04	AQ
Abliva publishes rights issue outcome	19/04	AQ
BioStock: Abliva's mission to become mitochondrial medicine powerhouse	08/04	AQ
Abliva publishes prospectus in connection with rights issue covered to 100 per cent by subscription and guarantee undertakings and admission to trading of newly issued shares	27/03	AQ
Resolutions at the Extraordinary General Meeting in Abliva AB (publ)	26/03	AQ
BioStock: Abliva's CEO comments on the proposed capital raise	29/02	AQ
Abliva AB Year-End Report January – December 2023	23/02	AQ
Notice of Extraordinary General Meeting of Abliva AB (publ)	22/02	AQ
The Board of Directors of Abliva resolves on a fully guaranteed rights issue of SEK 46 million and a directed issue of convertible bonds of SEK 42 million to prepare for the final stage of the FALCON study	22/02	AQ
BioStock: Abliva reaches enrollment goal	21/12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Abliva AB Deutsche Boerse AG

Equities

NTP

SE0002575340

Press Releases

Filters